Insider Transactions in Q2 2021 at Incyte Corp (INCY)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
283
+3.73%
|
$23,772
$84.13 P/Share
|
|
Jun 30
2021
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
238
+3.01%
|
$19,992
$84.13 P/Share
|
|
Jun 30
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
214
+1.24%
|
$17,976
$84.13 P/Share
|
|
Jun 30
2021
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
208
+4.12%
|
$17,472
$84.13 P/Share
|
|
Jun 30
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
690
+0.01%
|
-
|
|
Jun 29
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Open market or private sale
|
Direct |
27,194
-22.42%
|
$2,311,490
$85.37 P/Share
|
|
Jun 28
2021
|
Yao Wenqing EVP, Head of Discovery Chem |
SELL
Payment of exercise price or tax liability
|
Direct |
22,806
-15.83%
|
$1,938,510
$85.61 P/Share
|
|
Jun 28
2021
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,079
-18.44%
|
$1,876,715
$85.61 P/Share
|
|
Jun 18
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
255
+0.84%
|
$16,575
$65.36 P/Share
|
|
Jun 10
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,845
-12.65%
|
$334,515
$87.0 P/Share
|
|
Jun 10
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,845
+11.23%
|
$249,925
$65.42 P/Share
|
|
Jun 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
395
-1.47%
|
$33,180
$84.13 P/Share
|
|
May 26
2021
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+15.06%
|
-
|
|
May 26
2021
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+21.51%
|
-
|
|
May 26
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+10.27%
|
-
|
|
May 26
2021
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+20.55%
|
-
|
|
May 26
2021
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+29.33%
|
-
|
|
May 26
2021
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,923
+36.51%
|
-
|
|
May 26
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
3,846
+0.04%
|
-
|
|
May 14
2021
|
Baker Bros. Advisors LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
40,000
+0.38%
|
$720,000
$18.97 P/Share
|
|
May 03
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
396
-1.45%
|
$33,660
$85.4 P/Share
|
|
Apr 23
2021
|
Maria E Pasquale EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
127
+0.42%
|
$8,255
$65.36 P/Share
|
|
Apr 09
2021
|
Maria E Pasquale EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-1.7%
|
$40,843
$79.96 P/Share
|
|
Apr 01
2021
|
Dashyant Dhanak EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
396
-1.43%
|
$32,076
$81.57 P/Share
|